secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sanara MedTech Inc. (SMTI)
CIK:        0000714256
Form:       8-K
Filed at:   2023-08-16T23:59:59+00:00
Accession:  0001493152-23-029069
Event type: other_material
Sentiment:  negative
Materiality: 0.50
Item codes: 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Sanara MedTech clarifies Q2 sales per facility grew YoY but declined QoQ
------------------------------------------------------------------------

- On Aug 15, 2023 earnings call, Sanara MedTech said sales per facility were growing; today's 8-K clarifies it was YoY, not QoQ.
- Sequentially (Q2 2023 vs Q1 2023), sales per facility slightly declined.
- Metric calculated as monthly Surgical Products sales divided by number of facilities with revenue; quarterly is average of monthly.
- Surgical Products include CellerateRX, FORTIFY TRG, FORTIFY FLOWABLE, TEXAGEN, BiFORM, AMPLIFY, ALLOCYTE.
- Correction filed under Regulation FD to avoid misleading investors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/714256/000149315223029069/0001493152-23-029069-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/714256/000149315223029069/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-029069

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer